Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) insider William L. Macias sold 3,188 shares of the firm's stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $28.79, for a total transaction of $91,782.52. Following the sale, the insider now owns 365,144 shares of the company's stock, valued at $10,512,495.76. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Immunovant Stock Up 0.7 %
Immunovant stock opened at $29.47 on Friday. Immunovant, Inc. has a 52-week low of $24.67 and a 52-week high of $45.58. The firm has a market cap of $4.31 billion, a PE ratio of -15.51 and a beta of 0.66. The company's 50 day moving average is $30.09 and its two-hundred day moving average is $28.98.
Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by ($0.07). During the same quarter in the previous year, the firm posted ($0.57) earnings per share. On average, equities research analysts anticipate that Immunovant, Inc. will post -2.43 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Immunovant
Protect Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings | Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide.
It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Quest Partners LLC raised its holdings in Immunovant by 216.7% in the second quarter. Quest Partners LLC now owns 2,610 shares of the company's stock valued at $69,000 after acquiring an additional 1,786 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Immunovant in the 2nd quarter valued at $77,000. EntryPoint Capital LLC lifted its position in shares of Immunovant by 288.8% during the 1st quarter. EntryPoint Capital LLC now owns 2,912 shares of the company's stock worth $94,000 after purchasing an additional 2,163 shares during the last quarter. DNB Asset Management AS lifted its position in shares of Immunovant by 10.3% during the 2nd quarter. DNB Asset Management AS now owns 10,290 shares of the company's stock worth $271,000 after purchasing an additional 958 shares during the last quarter. Finally, Farallon Capital Management LLC acquired a new position in shares of Immunovant during the second quarter worth $317,000. 47.08% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages recently weighed in on IMVT. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immunovant in a research report on Monday, September 9th. JPMorgan Chase & Co. lowered their price target on Immunovant from $51.00 to $46.00 and set an "overweight" rating for the company in a report on Thursday, August 8th. Raymond James restated an "outperform" rating and issued a $36.00 price objective on shares of Immunovant in a report on Thursday, October 10th. Oppenheimer increased their target price on shares of Immunovant from $47.00 to $53.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 9th. Finally, UBS Group reduced their price target on shares of Immunovant from $42.00 to $41.00 and set a "buy" rating on the stock in a research note on Tuesday, August 13th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $48.91.
View Our Latest Stock Analysis on Immunovant
About Immunovant
(
Get Free Report)
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
